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Abstract
Abdominal aortic aneurysms (AAAs) expand as a consequence of extracellular matrix destruction, and vascular smooth
muscle cell (VSMC) depletion. Transforming growth factor (TGF)-beta 1 overexpression stabilizes expanding AAAs in rat.
Cyclosporine A (CsA) promotes tissue accumulation and induces TGF -beta1 and, could thereby exert beneficial effects on
AAA remodelling and expansion. In this study, we assessed whether a short administration of CsA could durably stabilize
AAAs through TGF-beta induction. We showed that CsA induced TGF-beta1 and decreased MMP-9 expression dose-
dependently in fragments of human AAAs in vitro, and in animal models of AAA in vivo. CsA prevented AAA formation at 14
days in the rat elastase (diameter increase: CsA: 131.9644.2%; vehicle: 225.9657.0%, P=0.003) and calcium chloride mouse
models (diameters: CsA: 0.7260.14 mm; vehicle: 1.1060.11 mm, P=.008), preserved elastic fiber network and VSMC
content, and decreased inflammation. A seven day administration of CsA stabilized formed AAAs in rats seven weeks after
drug withdrawal (diameter increase: CsA: 14.2615.1%; vehicle: 45.2613.7%, P=.017), down-regulated wall inflammation,
and increased aSMA-positive cell content. Co-administration of a blocking anti-TGF-beta antibody abrogated CsA impact on
inflammation, aSMA-positive cell accumulation and diameter control in expanding AAAs. Our study demonstrates that
pharmacological induction of TGF-beta1 by a short course of CsA administration represents a new approach to induce
aneurysm stabilization by shifting the degradation/repair balance towards healing.
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Introduction
Abdominal aortic aneurysms (AAAs) result from a protease-
driven destruction of the extracellular matrix (ECM) with no
significant aortic reconstruction, and account for 15 000 deaths
and 33 000 aortic repairs in the USA annually [1]. Current
treatments to prevent AAA rupture are hampered by a high post-
operative mortality rate for open surgery and a limited durability
after endovascular treatment, with comparable four-year all cause
mortality rates [2]. These limitations restrain the benefit of
screening programs, a strategy of public health interest, since most
detected patients carry small AAAs with currently no alternative to
surveillance [1].
Accordingly, research has focused on pharmacological
approaches to stop expansion of AAAs [3,4,5] by a regimen of
continuous drug administration to suspend the aortic destructive
p r o c e s s .W et h o u g h ti to fi n t e r e s tt od e v e l o pap h a r m a c o l o g i c
approach by which a short course of drug administration would
allow for a long term control of AAA diameter beyond
treatment interruption. Such a curative, rather than suspensive,
treatment would open up the possibility to use potent
modulators of the balance between aortic destruction and
repair with limited side effects. Using an endovascular gene
therapy approach, we have shown previously that a transient
overexpression of TGF-beta1 resulted in a long term stabiliza-
tion of diameter in formed, expanding AAAs [6]. As a
mechanistic explanation for the durability of this effect, we
documented induction of endogenous TGF-beta1 gene relaying
the rapidly neutralized transgene expression, and the correction
of VSMC depletion [6], a characteristic of AAAs [7]. This work
and other data from our laboratory [8] have pointed to the
potential of TGF-beta1 induction to reprogram the diseased
aortic wall at a cellular level, thereby restoring the capacity of
the repaired aneurysmal aorta to withstand hemodynamic stress
without further dilatation.
Cyclosporine A (CsA) is an immunosuppressive drug of the
calcineurin inhibitor family which induces TGF-beta1 gene
transcription and activates latent TGF-beta [9]. Numerous side
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nephropathy [10] and gingival hypertrophy [11], demonstrate its
ability to promote tissue accumulation. Notably, ECM accumu-
lation after CsA administration relies on TGF-beta activity [10].
Here, we tested the hypothesis that a short course of CsA
administration could shift the aneurysmal destruction/recon-
struction balance, and represent a new pharmacological strategy
to restore AAA wall integrity and stability. We demonstrate that
CsA induced TGF-beta1 in fragments of human AAAs in vitro and
in two animal models of AAA, and prevented AAA formation in
the elastase and the calcium chloride (CaCl2) models. Concordant
with our hypothesis, a short administration of CsA durably
stabilized the diameter of formed AAAs while increasing their
VSMC content. Moreover, the co-administration of an anti-
TGF-beta1 blocking antibody abrogated CsA impact on AAA
diameter control and VSMC content. We propose that induction
of TGF-beta1 by a short course of CsA administration represents
a new pharmacological approach to durably control aneurysm
diameter.
Results
CsA in human AAA explants
Because TGF-beta and MMP-9 are representative of the
reconstruction/destruction process occurring in the aneurismal
wall [12], we evaluated the impact of CsA on their secretion in
24 h-conditioned medium from explants from five different
human AAAs. Addition of CsA on AAA explants (within the
range of CsA concentrations observed in total blood under current
clinical use) dose-dependently increased TGF-beta1 and decreased
MMP-9 protein secretions (Figure 1).
CsA and AAA formation in rodents
CsA prevents AAA development. The effect of CsA was
evaluated in the rat elastase and mouse CaCl2 models. Fourteen
days after elastase perfusion, the increase in aortic diameter was
smaller in CsA- than in vehicle-treated rats (external diameter
increase: 131.9644.2 vs 225.9657.0%, respectively, P=0.0034)
(Figure 2A and 2B). Similarly, 14 days after CaCl2 application,
diameters were smaller in CsA- than in vehicle-treated mice
(external diameter: 0.7260.14 vs 1.1060.11 mm, respectively,
P=.008; internal diameter: 0.3760.04 vs 0.4860.07 mm,
respectively, P=.028) (Figure 2C and 2D). These results
demonstrate that CsA prevents AAA formation in two rodent
models.
CsA prevents VSMC loss and elastin destruction. Preven-
tion of AAA formation by CsA was accompanied by an increased
density of aSMA-positive cells in the neointima in elastase-perfused
aortas (Figure 3A) and by a higher number of aSMA-positive cells in
the media in mice (aSMA-positive cells per mm
2: 28566765 vs
16976732 in CsA- and vehicle-treated mice, respectively, P=.047)
(Figure 3B). Morever, in the CaCl2 model, CsA preserved the aortic
medial elastic network structure and density (elastic fiber surface:
14.564.2 and 7.462.9% of the aorta surface in CsA- and vehicle-
treated mice, respectively, P=.028) (Figure 3C). Altogether, these
results demonstrate that CsA prevents aortic wall destruction.
CsA increases TGF-beta1 and decreases MMP-9 expres-
sion. In mice, the prevention of AAA formation by CsA was
paralleled by a significant increase in anti-TGF-beta1 immunos-
taining localized in the medial layer (active TGF-beta staining:
77630 vs 37616% of the media surface in CsA- and vehicle-
treated mice, respectively, P=.047) (Figure 3D). CsA also reduced
total MMP-9 content in mouse AAA extracts (total MMP-9 level:
3.0162.22 vs 12.0868.41 pg/mg of total proteins in CsA- and
vehicle-treated mice, respectively, P=.008) (Figure 3E).
Pharmacologic induction of stabilization of expanding
AAAs by short-term CsA administration in rats
A short treatment with CsA induces long-term stabili-
zation of already-formed AAAs in rats. We then addressed
whether a short-term administration of CsA induces stabilization
of expanding AAAs durably after treatment interruption. For this
purpose, we used the xenograft model of AAA that mimics
important evolutive and structural features of human
atherosclerotic AAAs, such as constant expansion, inflammatory
and proteolytic burden, and intraluminal thrombus [13,14]. CsA
was administrated subcutaneously for seven days on already-
formed AAA. AAA remodelling was assessed 7 weeks after CsA
treatment interruption (Figure 4A).
As expected, the external diameter of abdominal aortas had
significantly increased 14 days after xenograft implantation and
was not different between CsA- and vehicle-treated rats at the
time of CsA treatment initiation (2.960.2 vs 3.360.5 mm,
respectively, NS) (Figure 4B). Whereas AAA diameter continued
to expand significantly in vehicle-treated rats (P,0.05), short CsA
treatment suspended AAA expansion up to 7 weeks after drug
withdrawal (diameter increase at 8 weeks: 14.2615.1 and
45.2613.7% in CsA- and vehicle-treated rats, respectively,
P=.017) (Figure 4B).
Induction of AAA stabilization by CsA parallels with
increased VSMC aortic content, decreased aortic inflam-
mation, a shift of MMP-dependent proteolytic balance and
an upregulation of TGF-beta1 expression. Stabilization of
expanding AAA by CsA was associated with a higher number of
aSMA-positive cells in the intima/thrombus, 7 weeks after drug
withdrawal (aSMA-positive cells per mm
2: 758361313 vs
Figure 1. CsA modulates TGF-beta1 and MMP-9 secretion from
human AAAs in vitro. Quantification of TGF-beta1 and MMP-9 in
24 h-conditioned media obtained from human AAA explants incubated
or not with CsA. Open circles represent individual protein levels and
closed circles represent means6SD. *P,.05 vs untreated-CsA group.
doi:10.1371/journal.pone.0028903.g001
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P=.017) (Figure 5A). Furthermore, CsA decreased monocyte-
macrophage density in formed AAAs (thrombus: 3676142 vs
9236290; media/adventitia: 5176149 vs 9626375 ED1-positive
cells per mm
2 in CsA- and vehicle-treated groups, respectively,
P=.049) (Figure 5B), as well as T lymphocyte infiltration
(thrombus: 209657 vs 694689; media/adventitia: 3646232 vs
7816181 R73-positive cells per mm
2 in CsA- and vehicle-treated
groups, respectively, P=.049) (Figure 5C). At the transcriptional
level, CsA led to a 4-fold increase in TGF-beta1 mRNA content
(Figure 5D), decreased MMP-9 and increased TIMP-1 mRNA
content in the thrombus (Figure 5E).
These results indicate that a short treatment with CsA increases
VSMC content in the aortic wall, induces TGF-beta expression,
decreases AAA inflammation and shifts the MMP-dependant
proteolytic balance towards inhibition.
induction of AAA stabilization by CsA is mediated by
TGF-beta
To assess the role of TGF-beta activity in CsA-induced AAA
stabilization, a TGF-beta-neutralizing antibody was administrated
to rats with expanding AAAs treated by CsA.
The stabilizing effect of CsA was conserved in control rats but
was abrogated in rats injected with the neutralizing antibody
(aortic diameter increase at 4 weeks: 10.9616.7 and 23.6614.5%
in neutralizing- and isotype control antibody-treated rats,
respectively, P=.049) (Figure 6A). In contrast, in animals treated
by vehicle instead of CsA, administration of the neutralizing
antibody against TGF-beta had no effect on AAA diameter
variation (aortic diameter increase at 4 weeks: 10.663.7 and
11.767.0% in neutralizing- and isotype control antibody-treated
rats, respectively, P=NS), demonstrating that the protective effect
of CsA on AAA expansion is mediated by TGF-beta.
Inhibition of CsA effects by TGF-beta1 neutralizing antibody
led to a significant decrease in aSMA-positive cell density
(media/adventitia: 7456346 vs 15206624; thrombus: 27006
362 vs 43006965 aSMA-positive cells per mm
2 in neutralizing-
and isotype antibody-treated groups, respectively, P=.001 and
.005), 3 weeks after CsA retrieval (Figure 6B). Besides, TGF-
beta neutralizing antibody injection was paralleled by an
increase in monocyte-macrophages infiltrating AAAs (media/
adventitia: 20316471 vs 8716279; thrombus: 15696832 vs
4126341 ED1-positive cells per mm
2 in neutralizing- and
isotype control antibody-treated groups, respectively, P,.01)
(Figure 6C).
These results demonstrate that long-lasting AAA stabilization by
a pulsed treatment with CsA is mediated by TGF-beta that
maintains aortic VSMC density and exerts inhibitory effects on
inflammatory cell recruitment.
Figure 2. CsA prevents AAA development in the rat elastase and the mouse CaCl2 models. A. Macroscopic pictures of representative rat
AAAs 14 days after elastase perfusion. B. External diameter increase at 14 days as a percentage of AAA diameters just after elastase perfusion. C.
Macroscopic pictures of mouse AAAs at 14 day. D. Mouse external and internal aortic diameter quantification. Open circles represent individual values
from vehicle- and CsA-treated animals and closed circles represent means6SD. *P,.05, **P,0.01 vs vehicle.
doi:10.1371/journal.pone.0028903.g002
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This is the first study to demonstrate that a short course of drug
administration can stabilize the diameter of expanding AAAs
durably after treatment withdrawal, by inducing TGF-beta1. CsA
induces TGF-beta1 in three models of AAA, including in human
AAA wall in vitro. CsA administration prevents AAA formation in
mice and rats and a seven day CsA administration durably
stabilizes formed, expanding AAAs in rats. Co-administration of
an anti-TGF-beta blocking antibody suppresses the inhibitory
action of CsA on ECM destruction, VSMC accumulation and
AAA expansion.
The rationale for using CsA in our study stems from its ability to
induce TGF-beta1 [10], a growth factor and cytokine with
pleı ¨otropic activities. CsA triggers TGF-beta1 expression in
VSMCs [15] and fibroblasts [16] in vitro, and in vivo in kidney
[17], gingival [11] and arterioles [18]. Here, we document that
CsA induces TGF-beta1 in two animal models of AAA and in
human samples of atherosclerotic AAAs.
In parallel with the enhanced TGF-beta signaling, our results
show that CsA administration prevents aneurysmal degeneration
in two rodent models of AAA, as previously evoked using a
cocktail of immunosuppressive drugs including CsA in the rat
elastase model [19]. Of interest, CsA treatment in our study
stabilized the diameter of formed, expanding AAAs in rats.
Importantly, co-administration of an anti-TGF-beta blocking
antibody suppressed the inhibitory action of CsA on AAA
expansion, showing that CsA exerted its stabilizing effect through
TGF-beta induction. At first sight this may appear contradictory
with data showing that exacerbated TGF-beta1 signaling in
monogenic defects is associated with aneurysms and dissections of
the ascending aorta in human and mice [12,20]. However, lesions
of the ascending aorta differ from atherosclerotic AAAs, with
respect to VSMC and ECM content, inflammation and thrombus
accumulation. In addition, VSMCs respond differently to TGF-
beta 1 according to their embryologic origin which differs along
the adult vascular tree [20]. Nevertheless, our data are in
agreement with our previous demonstration that TGF-beta1
overexpression by endovascular gene therapy stabilizes expanding
AAAs [6] and with a recent confirmation that TFG-beta 1 controls
aortic enlargement in a mouse model [21].
Transmural inflammatory cell infiltration is an important
feature of AAAs. Infiltrating leukocytes are thought to be a major
source of proteases directed against aortic ECM in human and
experimental AAAs [12,22]. CsA has been shown to decrease
MMP-9 expression in infarcted myocardium [23] and in rat
glomerular mesengial cells [24]. Moreover, CsA decreases MMP-2
activation in VSMCs, another cellular source of proteases in AAAs
Figure 3. CsA preserves VSMC and elastin content and modulates TGF-beta1 and MMP-9 expression in mouse AAAs. A.
Representative anti-aSMA immunostaining performed on AAA cross sections from vehicle- or CsA-treated rats, 14 days after elastase perfusion (red:
aSMA staining; blue : nuclei). B, C. Representative anti-aSMA (B) or elastin fibers (C) staining (right) and computer-assisted quantification (left)
performed on AAA cross sections from vehicle- or CsA-treated mice at 14 days. D. Representative anti-active TGF-beta1 staining (right) and computer-
assisted quantification (left) performed on AAA cross sections from vehicle- and CsA-treated mice at 14 days. E. ELISA quantification of MMP-9 on AAA
extracts from vehicle- and CsA-treated mice. Results are reported to the total protein level. Open circles represent individual values from vehicle- and
CsA-treated mice and closed circles represent means6SD. *P,.05, **P,.01 vs vehicle. NI : neointima; ILT: intraluminal thrombus. Scale bars : 50 mm.
doi:10.1371/journal.pone.0028903.g003
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CsA to favorably shift the proteolytic balance. CsA dose-
dependently decreases MMP-9 release by human AAA explants,
decreases aortic MMP-9 expression in the two animal models and
increased aortic TIMP-1 expression in rats. Down-regulation of
inflammation and proteolysis is likely to be one of the mechanisms
by which CsA prevents or stabilizes AAA expansion, as further
suggested by the preservation of elastic fiber network in the CaCl2
model. Furthermore, in the aneurysmal wall and/or thrombus in
rats, we show that CsA administration decreases infiltration by
macrophages and T lymphocytes, which have been shown to
increase the proteolytic burden in AAAs [26]. In a same way, CsA
has been shown to decrease inflammation in mechanically injured
arteries [27]. The mechanisms by which CsA may decrease
inflammation are multiple and controversial. Here, using a
blocking strategy, we demonstrate that TGF-beta activity is
required for CsA to down-regulate inflammation in formed AAAs.
VSMC loss is another histopathological important feature of
human AAAs [12]. Conversely, addition of VSMCs stabilizes the
diameter of expanding AAAs [28]. Here, we show that the
preventive and curative effects of CsA on AAAs are paralleled with
aortic wall VSMC accumulation. Those results are compatible
with the fact that one hallmark of CsA-induced vasculopathy in
organ transplantation is the inappropriate accumulation of
VSMCs [29]. Most importantly, in our study, the blocking
antibody strategy credit the notion that CsA-induced TGF-beta1
preserves and restores VSMC content in AAAs, while controlling
inflammation and proteolysis. Many data suggest that TGF-beta 1
is important in strengthening the vasculature, a concept supported
by our findings. TGF-beta1 promotes VSMC accumulation in
normal and atherosclerotic arteries [30,31]. Besides, in Angioten-
sin II-infused mice, exacerbation of aortic dilatation and rupture
upon neutralization of TGF-beta activity is paralleled by a
decrease in aortic VSMC content [21].
Of interest, our study further demonstrates that a seven day
treatment with CsA is sufficient to stabilize the diameter of
expanding AAAs seven weeks after treatment withdrawal. This
result supports the view that a short pulse of CsA administration
leads to a long-lasting reprogrammation of the aortic wall towards
healing, possibly through TGF-beta induction loop.
Clinical implications
Induction of healing represents a strategy to stabilize AAAs and
improve durability of current prosthetic endovascular approaches.
For this purpose, our laboratory and other groups have promoted
cell [28,32,33] or gene [6] therapy, two approaches hampered by
Figure 4. Short CsA treatment induces durable stabilization of AAAs in rats. A. Experimental design: rats with already formed, expanding
AAAs were treated for 7 days with vehicle or CsA. The percentage of diameter increase seven weeks after treatment withdrawal was calculated with
reference to AAA diameter at CsA introduction. Analysis of mRNA contents was performed at the end of the 7-day treatment, with the assumption
that biological changes at this delay provide early mechanistic explanations for the impact of CsA on the remodeling observed at 8 weeks. B. Impact
of the 7-day CsA administration on AAA expansion 7 weeks after treatment withdrawal. Open circles represent individual external aortic diameters
and closed circles represent means6SD. *P,.05.
doi:10.1371/journal.pone.0028903.g004
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From a pragmatic standpoint, correcting VSMC depletion in
AAAs using a pharmacological approach would obviate these
limitations in a clinical setting. Our study provide a model of
pharmacological induction of cellular repair of AAAs by turning-
on a self-promoting cytokine with pleı ¨otropic activities, as an
alternative to gene or cell therapy. Our data opens up the
possibility of using a short drug administration to control durably
AAA expansion in patients.
Methods
The study on human aortic samples was approved by a local
ethic committee (Comite ´ de Protection des Personnes, CPP
Mondor approval Nu09-017). An informed written consent was
obtained from all participants in the study. All experimental
procedures were conducted in conformity with European (86/
609/EEC) rules for animal care and have been approved by the
French Veterinary Department (approval Nu94-226).
Models of aneurysm
Human AAA explants. Fragments from five asymptomatic
human atherosclerotic AAAs (.55 mm) collected during elective
surgery in the Henri Mondor Hospital, were cultured in serum-
free medium with or without 1 or 2 mg/ml CsA (Sandoz, Rueil-
Malmaison, France) at 37uC. After 24 hours, explant-conditioned
media were snap-frozen.
The CaCl2 model in mice. AAAs were generated in 8 week-
old C57Bl/6 male mice (Charles River Laboratories) by periaortic
application of CaCl2 [34]. Mice received CsA (50 mg/kg daily,
n=5) or vehicle (n=5) intraperitoneously, starting two days
before CaCl2 application, until harvest. At day 14 after CaCl2
application, mice were anesthetized. After intracardiac perfusion
of saline, infrarenal aortas were cleared of surrounding tissue,
photographed in situ [34] and cut in two pieces, one being fixed in
4% paraformaldehyde and decalcified overnight in 0.5 M EDTA
before paraffin embedding, the other snap-frozen in liquid
nitrogen and kept at 280uC.
The elastase model in rats. AAA were generated in 250 g
male Wistar rats (Charles River Laboratories) by infusing five units
of pancreatic porcine elastase (Sigma, E-1250 lot No. 083K7655),
for 1 hour in the aortic lumen, as previously described [35]. Rats
received CsA (5 mg/kg/day, n=10) or vehicle (n=7)
subcutaneously for 14 days, starting immediately after elastase
infusion and wound closure. The subrenal aorta was
photographed in situ under beating heart immediately after
elastase infusion and 14 days later. AAAs were explanted, fixed
in 70% ethanol and embedded in paraffin.
The xenograft model in rats. AAAs were generated in
250 g male Fischer 344 rats (Charles River Laboratories) by
implanting an aortic xenograft [36]. Rats with developed AAAs
(e.g. 14 days after xenograft implantation) received
subcutaneously the vehicle (control group, n=5) or CsA 5 mg/
kg/day (n=6) for seven days. The subrenal aorta was
photographed in situ under beating heart, at the time of
initiation of CsA treatment, and eight weeks later, e.g. seven
weeks after treatment withdrawal, before euthanasia. AAAs were
fixed in 70% ethanol and embedded in paraffin. AAAs from six
others rats (three in each group) were harvested at day seven after
CsA treatment initiation. Thrombi and aneurysmal wall were
separately snap-frozen and kept at 280uC. To investigate the role
of TGF-beta in CsA-induced effects, rats with formed AAAs,
treated with CsA, received an intraperitoneal injection of
0.5 mg/kg of a pan-specific anti-TGF-beta monoclonal
antibody (clone 1D11, R&D Systems, Lille, France) three
times/week for two weeks, starting on the first day of CsA
treatment. This antibody has neutralizing properties against
TGF-beta1, 2 and 3 bioactivity [37]. As a control, we used the
isotype monoclonal antibody (clone 11711, R&D Systems). AAAs
were harvested three weeks after CsA withdrawal.
Histology, immuno-histochemistry and -fluorescence
Five mm thick paraffin-embedded cross sections were used for
mice and rat AAAs.
For histological analysis, sections were stained with orcein for
visualization of elastic fibers. For immuno-histochemical analysis,
sections were incubated with the following antibodies: mouse
monoclonal anti-alpha smooth muscle actin (aSMA, clone 1A4,
Sigma-Aldrich, Lyon, France), mouse anti-rat TCR alpha/beta
(Vector Laboratories, Abcys, Paris, France), mouse anti-rat
monocyte-macrophage (clone ED1, Serotec, Du ¨sseldorf, Ger-
many), and rabbit anti-active TGF-beta (Promega, Charbonnele,
France). When mouse primary antibody was used on mouse
sections, the Vector M.O.M kit was used, according to the
manufacturer’s instructions. After incubation with a biotin-
conjugated anti-species antibody (Vector Laboratories), immuno-
staining was amplified using peroxydase-conjugated streptavidin
complexes (Vector Laboratories) and peroxydase was detected
using VIP (Vector Laboratories) or Fast Red substrate System
(Dako, Trappes, France). Sections were counterstained with
hematoxylin, mounted in Eukitt and examined with a bright field
microscope (Zeiss, France).
For immuno-fluorescence study, sections were incubated with a
cyanine 3-conjugated anti-aSMA (clone 1A4, Sigma). Nuclei were
stained with DAPI and sections were mounted in Mowiol.
Fluorescence was examined with a fluorescence microscope
(AxioImager D1, Zeiss) in sequential scanning mode for double
detection of cyanine 3 and DAPI. Mosaic images were obtained
with a 206objective lens.
Computer-assisted morphometric analysis
In situ macroscopic and microscopic images were digitally
captured using the Axiovision 4.8 Software (Zeiss). Customized
programs were used to quantify the remodeling of the vessels, the
elastic fiber content, the inflammatory infiltrate, the VSMC
density and the TGF-beta expression level. The observer (SM) was
blinded to treatment allocation.
Remodeling of the vessels. External diameters were
measured from in situ images of infrarenal aortas using
Axiovision. Measurements of internal diameter in mice were
performed on cross-sections. The internal diameter corresponds to
the diameter of the equivalent circle having the same perimeter as
the aortic lumen.
Figure 5. CsA modulates VSCM density, inflammation and TGF-beta1, MMP-9 and TIMP-1 expression in already-formed AAAs in
rats. A, B and C. Representative immunostaining (lower panel) and quantification (upper panel)o faSMA-positive cells (A), macrophages (B) and T-
lymphocytes (C) performed on rat AAA cross sections, 7 weeks after CsA withdrawal. Open circles represent individual cell densities and closed circles
represent means6SD. D and E. RT-PCR semi-quantification of mRNAs encoding TGF-beta1, MMP-9 and TIMP-1, expressed as ratios to 18 s mRNAs
after a 7-day treatment. White columns: vehicle (n=5); black columns: CsA (n=6); *P,.05 vs vehicle. Scale bars: 50 mm.
doi:10.1371/journal.pone.0028903.g005
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quantified on histological cross-sections using AxioVision. Briefly,
the software allows for the selection and subsequent quantification
of pixel intensities in a chosen color spectrum (red-brown
corresponding to orcein staining). In order to minimize variations
between histological preparations, all microscopic slides were
stained simultaneously in the same orcein bath, the same range of
pixel intensity was used for all the quantifications, and the observer
was blinded for the treatment group. Results were expressed as a
percentage of total aortic surface.
Aortic Inflammatory Infiltrate, medial VSMC density and
active TGF-beta expression. Macrophages, T lymphocytes
andVSMCs inaorticsectionswerequantifiedafterimmunostaining
(see above) and expressed as the number of cells per mm
2 of total
aortic surface. The surface of active TGF-beta1 in aortic sections
was quantified after immunostaining and expressed as the
percentage of the media surface.
Elisa quantification of TGF-beta1 in human explant and
MMP-9 in mouse models
ELISA kits (R&D Systems) were used to quantify TGF-beta1 in
human aortic conditioned media or MMP-9 in mouse aortic
extracts. Proteins from mouse aortas were prepared by homog-
enizing tissues with a potter in a ice-cold extraction buffer (1%
Nonidet P-40 in 50 mM Tris-HCl, pH 7.4, containing 120 mM
NaCl, 1 mM EDTA, 50 mM NaF, and protease inhibitors
(Sigma-Aldrich)) after aorta pulverization with a MultiSample
Bio-Pulverizer (Biospec, Bartlesville, USA). Results were normal-
ized to total protein content, determined by BCA quantification.
Quantification of MMP-9 by zymography in human
explant
MMP-9 activity was evaluated by gelatin zymography [28].
Briefly, 5 mg of protein from human AAA conditioned medium
were subjected to a 10% SDS-PAGE containing 0.1% gelatin.
After electrophoresis, gels were washed in 2.5% Triton X-100 for
30 minutes, further incubated for 24 hours at room temperature
in 50 mmol/l Tris, pH 8.2 containing10 mmol/l CaCl2, and
finally stained with 0.008% Coomassie brilliant blue (Sigma
Chemical Co). Quantitative analysis of MMP-9 activity was
performed using QuantityOne software (Bio-Rad, Hercules, CA).
Analysis of mRNA levels by comparative RT-PCR
Because of the small amount of material available for separate
analysis of wall and thrombus in the rat model, tissues from 3 rats
were pooled by group and layer. Total RNAs from pooled luminal
thrombus or aneurysmal wall (media/adventitia) were extracted
with Trizol reagent (Invitrogen, Cergy Pontoise, France). Reverse
transcription (RT) was performed with random primers (Roche,
Meylan, France), M-MLV reverse transcriptase, dNTP, and
ribonuclease inhibitor (Eurobio, Les Ulis, France). Semiquantita-
tive PCR reactions were performed in presence of primers for the
domestic 18S gene RNA (QuantumRNA 18S Internal Standards
Kit, Ambion, Courtaboeuf, France) and specific rat primers:
Tissue Inhibitor of MetalloProteinase-1 (TIMP-1) (forward:5 9-
CCCCAGAAATCAACGAGAGACCA-39; reverse:5 9-ACACCC-
CACAGCCAGCACTAT-39), Matrix MetalloProteinase 9
(MMP-9) (forward:5 9-CTGCGTATTTCCATTCATCTT-39; re-
verse:5 9-ATGCCTTTTATGTCGTCTTCA-39) and TGFbeta-1
(forward:5 9-CGGACTACTACGCCAAAGAA-39; reverse:5 9-
TCAAAAGACAGCCACTCAGG-39).
PCR products were run on agarose gels with ethidium bromide.
Band intensity of amplified sequences were visualized under UV
light by a video camera and quantified with Gel Analyst software.
Results were expressed as the ratio between gene of interest and
18S signals.
Statistics
Quantitative data are expressed as means6SD. All statistical
tests were non parametric. Comparisons between more than two
groups were done with the Kruskall-Wallis test, and if significant
(P,0.05) followed by two-by-two comparisons. Mann-Whitney
test was used for all two-by-two comparisons. P,.05 was
considered as statistically significant.
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